blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3102225

EP3102225 - COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  21.02.2020
FormerGrant of patent is intended
Status updated on  27.08.2019
FormerExamination is in progress
Status updated on  12.10.2018
FormerRequest for examination was made
Status updated on  11.11.2016
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Novira Therapeutics Inc.
Welsh & McKean Roads
Mailstop SH 22-2-1
Spring House PA 19477 / US
[2019/15]
Former [2016/50]For all designated states
Novira Therapeutics Inc.
3805 Old Easton Road
Doylestown PA 18902 / US
Inventor(s)01 / HARTMAN, George D.
1529 Tennis Circle
Lansdale, PA 19446 / US
 [2016/50]
Representative(s)Cornish, Kristina Victoria Joy, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2020/13]
Former [2016/50]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date15746664.005.02.2015
[2016/50]
WO2015US14663
Priority number, dateUS201461936242P05.02.2014         Original published format: US 201461936242 P
[2016/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015120178
Date:13.08.2015
Language:EN
[2015/32]
Type: A1 Application with search report 
No.:EP3102225
Date:14.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2015 takes the place of the publication of the European patent application.
[2016/50]
Type: B1 Patent specification 
No.:EP3102225
Date:25.03.2020
Language:EN
[2020/13]
Search report(s)International search report - published on:RU13.08.2015
(Supplementary) European search report - dispatched on:EP29.09.2017
ClassificationIPC:A61K38/21, A61K31/167, A61K31/18, A61K31/395, A61P31/20
[2016/50]
CPC:
A61K31/45 (EP,RU,US); A61K31/40 (EP,KR,RU,US); A61K31/397 (EP,KR,RU,US);
A61K31/445 (EP,KR,RU,US); A61K38/21 (EP,KR,RU,US); A61K38/212 (EP,KR,RU,US);
A61P31/20 (EP); A61P43/00 (EP); A61K2300/00 (KR) (-)
C-Set:
A61K31/397, A61K2300/00 (US,EP);
A61K31/40, A61K2300/00 (US,EP);
A61K31/445, A61K2300/00 (EP,US);
A61K38/212, A61K2300/00 (US,EP);
A61K38/21, A61K2300/00 (EP,US)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/50]
Extension statesBA05.09.2016
ME05.09.2016
TitleGerman:KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON HBV-INFEKTIONEN[2016/50]
English:COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS[2016/50]
French:POLYTHÉRAPIE POUR LE TRAITEMENT D'INFECTIONS PAR LE VHB[2016/50]
Entry into regional phase05.09.2016National basic fee paid 
05.09.2016Search fee paid 
05.09.2016Designation fee(s) paid 
05.09.2016Examination fee paid 
Examination procedure25.08.2016Date on which the examining division has become responsible
05.09.2016Examination requested  [2016/50]
27.04.2018Amendment by applicant (claims and/or description)
15.10.2018Despatch of a communication from the examining division (Time limit: M04)
19.02.2019Reply to a communication from the examining division
28.08.2019Communication of intention to grant the patent
31.12.2019Fee for grant paid
31.12.2019Fee for publishing/printing paid
31.12.2019Receipt of the translation of the claim(s)
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
10.02.2017Renewal fee patent year 03
14.02.2018Renewal fee patent year 04
13.02.2019Renewal fee patent year 05
13.02.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.02.2015
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MK25.03.2020
MT25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
TR25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
[2026/04]
Former [2024/41]HU05.02.2015
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MK25.03.2020
MT25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2024/22]HU05.02.2015
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MK25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2023/30]HU05.02.2015
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2023/27]HU05.02.2015
AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/41]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/24]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/11]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/08]CZ25.03.2020
DK25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/50]CZ25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/49]CZ25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/48]FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/47]FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
Former [2020/46]FI25.03.2020
HR25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
Former [2020/45]FI25.03.2020
HR25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
Former [2020/39]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
Former [2020/38]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
NO25.06.2020
GR26.06.2020
Former [2020/37]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
NO25.06.2020
Former [2020/35]FI25.03.2020
NO25.06.2020
Documents cited:Search[X] WO0145712  (BAYER AG et al.) [X] 1,2 * pages 58-59,69; claim 13 *
 [XPY] WO2014106019  (PHILADELPHIA HEALTH & EDUCATIO et al.) [XP] 1-5 * page 128, paragraph 379 * * pages 238-238, paragraph 670 *[Y] 1-18
 [XPY] WO2014165128  (NOVIRA THERAPEUTICS INC et al.) [XP] 1-4 * pages 3,4 *[Y] 1-18
 [E] WO2015172128  (UNIV INDIANA RES & TECH CORP et al.) [E] 1-5 * pages 6,20 * * pages 17-18, paragraphs 30-32 *
 [E] WO2015118057  (JANSSEN SCIENCES IRELAND UC et al.) [E] 1,2 * page 19 *
International search[X] WO2013096744  (NOVIRA THERAPEUTICS INC et al.) [X] 1-9, 11-15, 17, 18 * , abstract, pp. 4-8, 23-24, 159, 160, 171-176 *
 [A] WO9823285  (SMITHKLINE BEECHAM PLC et al.) [A] 1-9, 11-15, 17, 18 * , claims 3, 12 *
 [A]   CAMPAGNA, MATTHEW R. ET AL.: "Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids.", JOURNAL OF VIROLOGY, vol. 87, no. 12, pages 6931 - 6942, XP055153462

DOI:   http://dx.doi.org/10.1128/JVI.00582-13
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.